Protein kinase inhibitor

Results: 181



#Item
1Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro

Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro

Add to Reading List

Source URL: www.eumbrella.org

Language: English - Date: 2016-02-26 09:44:29
    2Journal of Cellular Biochemistry 103:972–Raf Kinase Inhibitor Protein Positively Regulates Cell–Substratum Adhesion While Negatively Regulating Cell–Cell Adhesion Kevin T. Mc Henry,1 Roberto Montesano,2

    Journal of Cellular Biochemistry 103:972–Raf Kinase Inhibitor Protein Positively Regulates Cell–Substratum Adhesion While Negatively Regulating Cell–Cell Adhesion Kevin T. Mc Henry,1 Roberto Montesano,2

    Add to Reading List

    Source URL: biochemweb.net

    Language: English - Date: 2015-09-29 23:11:38
      3Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio

      Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio

      Add to Reading List

      Source URL: www.pmda.go.jp

      Language: English - Date: 2016-08-04 23:27:33
      4ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced

      ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced

      Add to Reading List

      Source URL: www.zailaboratory.com

      Language: English - Date: 2015-11-24 01:50:17
      5HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC. COTELLIC (cobimetinib) tablets, for

      HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC. COTELLIC (cobimetinib) tablets, for

      Add to Reading List

      Source URL: www.accessdata.fda.gov

      Language: English - Date: 2015-11-10 11:42:30
      6Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio

      Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio

      Add to Reading List

      Source URL: www.pmda.go.jp

      Language: English - Date: 2016-08-04 23:27:38
      7TYKERB (lapatinib) tablets

      TYKERB (lapatinib) tablets

      Add to Reading List

      Source URL: www.accessdata.fda.gov

      Language: English - Date: 2010-02-01 09:50:51
      8Letter pubs.acs.org/acsmedchemlett Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases Jing Dong,*,† Hongtao Zhao,† Ting Zhou,† Dimitrios Spiliotopoulos,† Chitra Rajendra

      Letter pubs.acs.org/acsmedchemlett Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases Jing Dong,*,† Hongtao Zhao,† Ting Zhou,† Dimitrios Spiliotopoulos,† Chitra Rajendra

      Add to Reading List

      Source URL: www.biochem-caflisch.uzh.ch

      Language: English - Date: 2015-03-30 11:57:31
      9Technology Opportunity, Ref. No. UZNovel nanomolar inhibitor of Eph tyrosine kinases New small molecule inhibitors of Eph kinases have been developed which have potential therapeutic application in angiogenesis

      Technology Opportunity, Ref. No. UZNovel nanomolar inhibitor of Eph tyrosine kinases New small molecule inhibitors of Eph kinases have been developed which have potential therapeutic application in angiogenesis

      Add to Reading List

      Source URL: www.switt.ch

      Language: English - Date: 2014-02-01 16:41:28
      10CrossMark_Color_Stacked_p

      CrossMark_Color_Stacked_p

      Add to Reading List

      Source URL: www.biochem-caflisch.uzh.ch

      Language: English - Date: 2014-08-22 09:07:41